QUIET · Top news

Merck-Moderna mRNA melanoma vaccine cuts recurrence risk 42% in Phase 3 trial

Phase 3 trial: first personalized mRNA cancer vaccine cut melanoma recurrence 42%.

Significance 8/10Merged

AT A GLANCE

Developments
27
Articles
124
5 in the last 24 h
Sources
91
4 in the last 24 h
Since

Timeline

  2. Sunday report revisits Moderna's 18% stock slide after the vaccine data leak

    Original on theenterpriseworld.com 1 source

  3. Melanoma expert Paolo Ascierto says mRNA vaccines open a new chapter in melanoma treatment

    Original on oncodaily.com 1 source

  4. Saturday investor coverage recaps the Phase 3 trial's 42% recurrence-risk cut

    Original on marketbeat.com 1 source

  5. Full INTerpath-001 data at ESMO detail distant-metastasis, survival, subgroup and safety results

    Original on cancernetwork.com +3 similar4 sources

    3 similar copies from other outlets

  6. Commentary contrasts the vaccine's medical breakthrough with Moderna's Wall Street meltdown

    Original on worldofdtcmarketing.com 1 source

  7. Medici CMO Nicholas Restifo reflects on 20 years of melanoma immunotherapy after the 42% result

    Original on oncodaily.com 1 source

  8. Merck executive calls the ESMO data leak 'unfortunate' but says 'it is what it is'

    Original on fiercebiotech.com 1 source

  9. Mumbai oncologist Amol Akhade hails the first randomized trial of a personalized mRNA cancer vaccine

    Original on oncodaily.com 1 source

  10. Hours later, NPR and local TV report the vaccine's promising melanoma trial results

    Original on wfae.org +14 similar15 sources

    3 similar copies from other outlets

  11. Moroccan oncologist Nabil Ismaili hails the first validated mRNA vaccine in melanoma

    Original on oncodaily.com 1 source

  12. CNN, ABC and Healio carry the vaccine's 42% recurrence-risk cut to wider audiences Friday

    Original on wishtv.com +7 similar8 sources

    3 similar copies from other outlets

  13. Merck CEO plays down cost concerns, saying cost won't limit access to intismeran

    Original on stocktwits.com +1 similar1 source

  14. Oncologists call the vaccine data a major advance despite Wall Street's negative reaction

    Original on cnbc.com 1 source

  15. Reports highlight that 82% of vaccinated patients remained cancer-free after two years

    Original on gizmodo.com +2 similar3 sources

    2 similar copies from other outlets

  16. Citi questions whether the vaccine's benefit justifies individualized tumor harvesting and manufacturing

    Original on stocktwits.com +1 similar1 source

  17. Moderna shares extend their decline in Friday premarket trading

    Original on benzinga.com +1 similar2 sources

    1 similar copy from other outlets

  18. Oncology trade press details intismeran-pembrolizumab's 42% cut in melanoma recurrence

    Original on targetedonc.com +4 similar5 sources

    2 similar copies from other outlets

  19. Friday coverage calls it the first personalised cancer vaccine to cut recurrence in a major trial

    Original on bbc.co.uk +5 similar4 sources

    2 similar copies from other outlets

  20. New York Times calls the tailored melanoma shot the realization of a long-held 'dream'

    Original on newser.com 1 source

  21. Even after the slide, Moderna stock remains up more than 530% for 2026

    Original on beincrypto.com 1 source

  22. UK reports hail the 'bespoke' mRNA vaccine's significant cut in melanoma recurrence or death

    Original on theguardian.com 1 source

  23. Moderna heads for its worst week in three months as an analyst calls it 'do-not-trade'

    Original on stocktwits.com +2 similar2 sources

    1 similar copy from other outlets

  24. OncologyTube cites a 49% recurrence-risk cut (HR 0.51) for intismeran plus Keytruda ahead of ESMO

    Original on oncologytube.com 1 source

  25. KEY

    Companies publish full INTerpath-001 results early, ahead of ESMO presentation

    Original on fiercebiotech.com +33 similar30 sources

    3 similar copies from other outlets

  26. ESMO confirms data embargo was breached; Moderna shares settle down about 18-20%

    Original on stocktwits.com +5 similar5 sources

    3 similar copies from other outlets

  27. Moderna shares plunge as much as 25% after partial trial data leak, shedding $24 billion

    Original on ksl.com +7 similar7 sources

    3 similar copies from other outlets

  28. Merck and Moderna say vaccine plus Keytruda cut melanoma death or recurrence risk by 42%

    Original on the-independent.com +8 similar9 sources

    3 similar copies from other outlets

ACTIVITY

27 developments, oldest to newest. Select one to jump to it.

OldestNewest →

COVERAGE

10 top outlets

ABC News · AP · BBC · CNBC · CNN · Guardian

DETAILS
Category
Top news · Health
Rank in tab
#33
Event id
ev_1GHEqT4q
Public since
Merged from
Intismeran Autogene: 49% Lower Melanoma Recurrence Ahead of ESMO
Timeline
Editor (LLM), frozen once published